V8 Peptides — Engineered Performance
Research Library
Growth Hormone Peptides: GHRH vs Ghrelin Receptor
Research CompoundsComparison

Growth Hormone Peptides: GHRH vs Ghrelin Receptor

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What are growth hormone peptides? A loose group of research peptides that act on one of two receptors: the GHRH receptor (sermorelin, CJC-1295, tesamorelin) or the ghrelin receptor GHS-R (ipamorelin, GHRP-2, GHRP-6, hexarelin). Each class needs its own readout, cAMP for the first and calcium signaling for the second, and its own reference ligand. Secretagogues cause endogenous GH release and are not GH itself. Plan volumes with the calculator and check lots on the COA page. For laboratory research use only.

"Growth hormone peptides" is a search phrase, not a pharmacological class. It covers at least two unrelated receptor families, short-lived and long-lived molecules, and compounds that are blended on purpose. A researcher who lumps them into one group will choose the wrong control, the wrong readout or the wrong comparison. This guide sorts the group by receptor and by chemistry, gives each class its own bench logic, and explains why the standard experimental design for one class does not carry over to the other. It describes laboratory research materials only.

Start with the physiology, not the product names

Growth hormone (GH) leaves the pituitary somatotroph in pulses. Two hypothalamic peptides shape those pulses: GHRH stimulates release and somatostatin restrains it. A third pathway, discovered later, runs through the growth hormone secretagogue receptor (GHS-R), which responds to the stomach peptide ghrelin. The comprehensive review of neuroendocrine control of GH secretion places all three, along with feedback from IGF-I, into a single control system (Müller et al., 1999). Every "GH peptide" on the market works on one of the two stimulating arms of that system.

The history explains the two arms. Growth-hormone-releasing factor was isolated and characterized in the early 1980s from a human pancreatic tumor that caused acromegaly (Guillemin et al., 1982). Synthetic compounds that released GH through a different, as yet unidentified receptor were already known as growth hormone secretagogues, and the endogenous ligand for their receptor was not purified until 1999, when ghrelin was identified in rat stomach as a 28-amino-acid peptide with an n-octanoylated serine at position 3 that specifically releases GH both in vivo and in vitro (Kojima et al., 1999). The abstract of that paper states that there was reason to believe in a mechanism for regulating GH release distinct from regulation by GHRH. The field of synthetic secretagogue design is reviewed in an Endocrine Reviews article on peptidomimetic regulation of GH secretion (Smith et al., 1997).

Class 1: GHRH-receptor agonists

These compounds are analogs or fragments of GHRH. They bind the GHRH receptor and raise cAMP in somatotrophs. The family includes the 29-residue fragment sermorelin, the stabilized tetrasubstituted 1-29 analog sold as CJC-1295 (no DAC), the version with a drug affinity complex, and the full-length stabilized analog tesamorelin.

CompoundDesign featureLibrary overviewProduct page
SermorelinTruncated 1-29 fragment of native GHRHsermorelin overviewsermorelin
CJC-1295 (no DAC)Amino-acid substitutions to stabilize the 1-29 sequenceno DAC overviewCJC-1295 no DAC
CJC-1295 with DACAdds a drug affinity complex for albumin bindingDAC overviewSee the overview
TesamorelinFull-length 1-44 with N-terminal trans-3-hexenoyl grouptesamorelin overviewtesamorelin

Because their receptor is shared, comparisons within this class are comparisons of stability, potency and duration, not of mechanism. The stability argument is the design logic: native GHRH is inactivated quickly, so analogs protect or substitute residues near the N-terminus. The head-to-head discussions are in CJC-1295 vs sermorelin, tesamorelin vs sermorelin and DAC vs no DAC.

Class 2: ghrelin-receptor (GHS-R) agonists

These compounds act on a different receptor. Peptides such as ipamorelin, GHRP-2 and GHRP-6, and hexarelin are synthetic GH secretagogues that engage the receptor ghrelin uses. In practice they are short peptides, five or six residues, and they differ in selectivity and in how much they affect other hormones. The library compares them in ipamorelin vs GHRP-2, ipamorelin vs GHRP-6 and hexarelin vs ipamorelin, with the single-compound background in ipamorelin research overview and what is ipamorelin. The vial is described on the ipamorelin product page.

The experimental consequence is that a GHS-R agonist needs ghrelin or a reference secretagogue as its positive control and a different pathway readout, most often calcium mobilization through Gq coupling in receptor-expressing cells, not the cAMP readout that suits GHRH-receptor compounds. A design that tests an ipamorelin-type compound with a cAMP assay in a GHRH-receptor cell line will return nothing and will not mean the compound is inactive.

Side-by-side: how the two classes differ at the bench

FeatureGHRH-receptor agonistsGHS-R (ghrelin-receptor) agonists
ReceptorGHRH receptorGrowth hormone secretagogue receptor
Endogenous reference ligandGHRHGhrelin
Primary signaling readoutcAMP accumulationCalcium mobilization, IP accumulation
Typical molecule size29 to 44 residuesFive to six residues
Main stability issueN-terminal dipeptidyl peptidase cleavageShort peptide, generally simpler; adsorption and oxidation still matter
Cell systemReceptor-expressing cells or primary pituitary cellsReceptor-expressing cells or primary pituitary cells
Feedback sensitivitySomatostatin and IGF-I feedbackSame pituitary feedback, plus ghrelin-system modulation

Why blends exist, and what they can and cannot show

Because the two receptors are independent, activating both is a design question in its own right. Pairing a GHRH-receptor agonist with a GHS-R agonist is a way to ask whether the two inputs interact in somatotroph cells, and commercial blends exist to supply the pair in a fixed ratio. The V8 catalog has the CJC-1295 (no DAC) + ipamorelin blend and the tesamorelin + ipamorelin blend. Explanations are in CJC-1295 and ipamorelin blend explained, tesamorelin and ipamorelin blend explained and, for the choice between a blend and two vials, blend vs separate vials.

A fixed-ratio blend can ask whether the combination changes a readout, and it cannot attribute the change to either component. Answering that needs single-compound arms at the concentration each has in the blend, and ideally a concentration matrix so that additivity and synergy can be separated with a formal model. This is the same logic as for any combination in cell biology.

A common source of confusion: secretagogues versus GH itself

Secretagogues cause endogenous GH release; they are not growth hormone. Recombinant GH is a 191-amino-acid protein that acts on the GH receptor directly, and a secretagogue experiment measures upstream events: release from pituitary cells, cAMP or calcium signaling in receptor cells, and downstream IGF-I production in tissues that respond to GH. The comparison is set out in growth hormone secretagogues vs HGH. For a controlled study the distinction determines which controls are valid: recombinant GH is a positive control for the downstream GH-receptor step, but it is the wrong control for the pituitary step.

Readouts matched to the question

QuestionSuitable systemReadoutClass it fits
Does a compound activate its receptor?Cells expressing one receptorcAMP (GHRH-R) or calcium (GHS-R)Each class with its own receptor
Does it release GH from pituitary cells?Primary pituitary cultureGH in medium by immunoassayBoth
Is it stable in serum?Serum or purified peptidase incubationLC-MS of the intact peptide over timeMainly GHRH analogs
Do two compounds interact?Same cells, concentration matrixGH release, cAMP and calcium measured togetherPairs across classes
Does the vial match its label?Receiving inspectionHPLC trace, mass, appearanceEvery class

Pulsatility is an extra consideration for any in-vivo or perfused-pituitary design. A single time point after exposure misses amplitude and frequency changes, so timed series are needed, as detailed in the tesamorelin material linked above.

Choosing a cell system

Two practical choices dominate. Recombinant cell lines that express a single receptor give clean pharmacology and make it easy to compare compounds, but they lack somatostatin tone, feedback and neighboring cell types. Primary pituitary cultures keep the native cell mix and the native receptor ratio, so they report on release, but donor variation, culture age and the proportion of somatotrophs change the signal from batch to batch. A reasonable program starts in the recombinant system to establish potency and selectivity, then moves to primary cultures to ask about release, and handles any in-vivo question as a separate study with its own sampling design. In every system, write down the passage number, plating density, medium and serum lot, because GH release and receptor expression both drift with them. Where a result appears only in one system, say so in the report and avoid wording that suggests it generalizes.

Handling, quality and where to look next

All of these compounds arrive as lyophilized powders with storage lines that follow the same pattern: refrigerate at 2–8 °C, hold at −20 °C for the long term, and protect from heat, moisture and light. Reconstitution arithmetic is the same for each: concentration equals mass divided by diluent volume, and the reconstitution calculator performs the conversion. Lot documents, including HPLC traces, are on the COA page, and the purity-testing pages for each compound explain how to read them, for example ipamorelin purity testing, sermorelin purity testing and CJC-1295 and ipamorelin purity testing. The wider catalog context is in what are research peptides, and the compounds are listed in the research shop.

Frequently asked questions

What are growth hormone peptides?

A loose group of research peptides that influence growth hormone release. They fall into two receptor classes: GHRH-receptor agonists and ghrelin-receptor (GHS-R) agonists.

Which compounds are GHRH-receptor agonists?

Sermorelin, CJC-1295 with and without DAC, and tesamorelin are analogs or fragments of growth-hormone-releasing hormone.

Which compounds act on the ghrelin receptor?

Ipamorelin, GHRP-2, GHRP-6 and hexarelin are synthetic secretagogues that engage the growth hormone secretagogue receptor, the receptor for ghrelin.

When was the ghrelin receptor ligand identified?

A 1999 Nature paper reported ghrelin as the endogenous ligand, a 28-amino-acid peptide from rat stomach with an n-octanoylated serine at position 3.

Why do the two classes need different assays?

They use different receptors and signaling pathways. GHRH-receptor compounds are read by cAMP, while GHS-R compounds are usually read by calcium mobilization.

Is a secretagogue the same as growth hormone?

No. Secretagogues cause endogenous GH release, while recombinant GH acts directly on the GH receptor. They need different controls.

Why are two-compound blends sold?

Because the two receptor classes are independent, combining them is a way to ask whether the inputs interact. A fixed ratio cannot separate the contribution of each component.

How can a lab separate additive from synergistic effects?

Run each compound alone at its blend concentration, then a concentration matrix of the pair, and analyze with a formal synergy model.

Why is pulsatility important in GH experiments?

GH is released in pulses shaped by GHRH and somatostatin, so one time point can miss changes in amplitude or frequency.

How are research vials stored?

The product pages state refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Research-use statement

Everything on this page is educational background for laboratory research use only. V8 Peptides products are sold as research materials, not for human or animal consumption, and nothing here describes a use outside the laboratory. Browse the research catalog, check lot documents on the COA page, or run volumes through the reconstitution calculator.

Related reading: What Are Peptides? A Beginner's Guide to the Science, Why Peptides Matter in Biomedical Research, Why Sexual Desire Declines With Age: What Studies Report.

References

  1. Müller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511-607. doi:10.1152/physrev.1999.79.2.511
  2. Guillemin R, Brazeau P, Böhlen P, Esch F, Ling N, Wehrenberg WB. Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science. 1982;218(4572):585-587. doi:10.1126/science.6812220
  3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. doi:10.1038/45230
  4. Smith RG, Van der Ploeg LHT, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621-645. doi:10.1210/edrv.18.5.0316

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.